Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bayer AG | 1,868 |
| 2 | Merck and Co Inc | 808 |
| 3 | AbbVie Inc | 681 |
| 4 | Merck KGaA | 620 |
| 5 | Vertex Pharmaceuticals Inc | 370 |
| 6 | Incyte Corp | 289 |
| 7 | Roche Holding AG | 276 |
| 8 | Samsung Biologics Co Ltd | 248 |
| 9 | Organon and Co | 226 |
| 10 | Arvinas Inc | 219 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 12,816 |
| 2 | A61K | Medicinal preparations | 12,357 |
| 3 | C07D | Heterocyclic compounds | 7,954 |
| 4 | C07K | Peptides | 2,926 |
| 5 | C12N | Microorganisms, enzymes | 1,142 |
| 6 | G01N | Investigating / analysing materials | 992 |
| 7 | Y02A | Climate change adaptation | 774 |
| 8 | C07C | Acyclic and carbocyclic compounds | 701 |
| 9 | C07B | General methods of organic chemistry | 623 |
| 10 | C12Q | Measuring/testing involving enzymes | 544 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF | 2010 | Endo International PLC | 9 |
| Histrelin synthesizing method | 2013 | 3 | |
| Method for synthesizing histrelin in full liquid phase | 2021 | 1 | |
| Method for specifically synthesizing histrelin | 2017 | 1 | |
| IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF | 2010 | Endo International PLC | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Amicur Farkas | Shaare Zedek Medical Center | 8 |
| 2 | Boris Chertin | Shaare Zedek Medical Center | 8 |
| 3 | K. Sundaram | Population Council | 7 |
| 4 | Erica A. Eugster | Indiana University – Purdue University Indianapolis | 7 |
| 5 | Irving M. Spitz | Ben-Gurion University of the Negev | 7 |
| 6 | David R. Meldrum | University of California, Los Angeles | 6 |
| 7 | Marcelle I. Cedars | University of California, Los Angeles | 6 |
| 8 | John K.H. Lu | University of California, Los Angeles | 6 |
| 9 | Howard L. Judd | University of California, Los Angeles | 5 |
| 10 | J.L. McGuire | Ortho Clinical Diagnostics (United States) | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Successful Treatment of Severe Premenstrual Syndrome by Combined Use of Gonadotropin-Releasing Hormone Agonist and Estrogen/Progestin* | 1991 | 159 | Menstrual Health and Disorders |
| Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. | 1987 | 133 | Endometriosis Research and Treatment |
| The Role of Gonadotropin-Releasing Hormone in Murine Preimplantation Embryonic Development* | 1999 | 114 | Reproductive Biology and Fertility |
| Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease* | 1987 | 96 | Reproductive Biology and Fertility |
| A Gonadotropin Releasing Hormone Analogue Prevents Cyclical Attacks of Porphyria | 1990 | 95 | Heme Oxygenase-1 and Carbon Monoxide |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of histrelin?
Which companies hold the most patents related to histrelin?
What is the patent coverage for histrelin technology?
Which researchers have published the most papers on histrelin?
What are the main research topics associated with histrelin in the literature?